Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

15 Jan 2020 10:32

RNS Number : 8891Z
IXICO plc
15 January 2020
 

15 January 2020

 

IXICO plc

("IXICO" or the "Company")

 

Exercise of Options and PDMR Dealings

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it received notification on 10 January 2020 that John Hall, SVP Corporate Development and PDMR, exercised 75,000 options with an exercise price of 34p.

 

The Company has also received notification on 10 January 2020 that Robin Wolz, SVP Research & Development and PDMR, exercised 83,882 options of which 45,176 were exercisable at 30.5p and 38,706 were exercisable at 34p. The 83,882 shares were sold to a third party at an average price of 87.6p.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

John James Hall

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Corporate Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

34p

75,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

75,000 shares

- Price

34p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Robin Wolz

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

IXICO plc

b)

 

LEI

 

 

2138005M1F59O6HWSA97

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

 

b)

 

Nature of the transaction

 

 

Exercise of options

c)

 

Price(s) and volume(s)

 

 

 

 

 

Exercise Price(s)

Volume(s)

 

 

30.5p

45,176

 

 

34p

38,706

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

83,882 shares

- Price

32.1p

e)

 

Date of the transaction

 

 

10/1/20

f)

 

Place of the transaction

 

 

N/A

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

 

Name

 

 

Robin Wolz

 

 

2

 

Reason for the notification

 

 

a)

 

Position/status

 

 

PDMR (SVP Research & Development)

 

b)

 

Initial notification /Amendment

 

 

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

 

Name

 

 

IXICO plc

 

b)

 

LEI

 

 

2138005M1F59O6HWSA97

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

 

 

Identification code

GB00BCLY7L40

 

 

 

b)

 

Nature of the transaction

 

 

Sale

 

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) Date

Volume(s)

 

 

 

92p 10/1/20

18,395

 

 

 

90p 13/1/20

18,395

 

 

 

85p 13/1/20

47,092

 

 

 

 

 

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

83,882 shares

 

 

- Price

87.6p

 

 

e)

 

Date of the transaction

 

 

10/1/20 and 13/1/20

 

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur/Manel Mateus

ixico@optimumcomms.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBELFFBFLXBBB
Date   Source Headline
16th Dec 20247:00 amRNS-RCommercial agreement with PETNET Solutions Inc
10th Dec 20247:00 amRNSContract Win
4th Dec 202411:35 amRNSShare Option Award & PDMR Dealings
4th Dec 20247:00 amRNSFinancial Results for year ended 30 September 2024
25th Nov 20247:00 amRNSNotice of Results and Investor Presentation
31st Oct 20247:00 amRNSShare Option Awards & PDMR Dealing
30th Oct 20244:50 pmRNSHolding(s) in Company
29th Oct 20244:00 pmRNSHolding(s) in Company
29th Oct 202410:58 amRNSHolding(s) in Company
28th Oct 20244:59 pmRNSHolding(s) in Company
28th Oct 202411:00 amRNSDirector/PDMR Shareholdings
25th Oct 202412:55 pmRNSResult of GM, Issue of Equity & TVR
22nd Oct 20243:00 pmRNSCorrection of clerical error
17th Oct 20247:00 amRNSHolding(s) in Company
16th Oct 20247:00 amRNSDirector/PDMR Shareholding
15th Oct 20247:00 amRNSResult of Retail Offer
10th Oct 20241:30 pmRNSExercise of Options & Director/PDMR Purchase
9th Oct 20247:00 amRNSResult of Placing and Subscription
8th Oct 20244:40 pmRNSRetail Offer
8th Oct 20244:35 pmRNSPlacing and Subscription
14th Aug 20247:01 amRNSTrading Update
14th Aug 20247:00 amRNSContract Win
5th Aug 20247:00 amRNSBoard Appointment
29th Jul 20247:00 amRNSFurther progress in HD consortium
20th Jun 20245:45 pmRNSHolding(s) in Company
19th Jun 20247:00 amRNSContract Win
23rd May 20247:00 amRNSContract Win
21st May 20247:00 amRNSHalf-year Report
7th May 20247:00 amRNSNotice of half year results
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.